Prevalence of factor V Leiden mutation in various populations

被引:0
|
作者
Herrmann, FH
Koesling, M
Schroder, W
Altman, R
Bonilla, RJ
Lopaciuk, S
PerezRequejo, JL
Singh, JR
机构
[1] HOSP NATL NINOS,SAN JOSE,COSTA RICA
[2] INST HEMATOL & BLOOD TRANSFUS,WARSAW,POLAND
[3] BANCO SANGRE DE CARABOBO,VALENCIA,VENEZUELA
[4] UNIV AMRITSAR,CTR GENET DISORDERS,AMRITSAR,PUNJAB,INDIA
关键词
frequency of APC resistance; factor V Leiden in Middle and South America; India;
D O I
10.1002/(SICI)1098-2272(1997)14:4<403::AID-GEPI5>3.0.CO;2-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Resistance to activated protein C (APC) is the most common inherited risk factor for venous thrombosis. Most cases of APC resistance are caused by the point mutation nt 1691 G-A in factor V gene, referred to as factor V Leiden mutation. As initially shown in a Dutch population, this mutation has a carrier rate of 2.9%, the most frequent genetic disposition for thrombophilia and deep venous thrombosis. By large-scale epidemiological studies we have determined the prevalence of factor V Leiden mutation in populations from Poland (200), Argentina (215), Venezuela (126), Costa Pica (196), and India (150). The prevalences have been estimated for Poland (Warsaw) 5.0%, Argentina (Buenos Aires) 5.1%, Venezuela (Valencia) 1.6%, Costa Pica (San Jose) 2.0%, and India (Punjab) 1.3%. Based on worldwide distribution, it can be hypothesized that the factor V Leiden mutation has originated and accumulated in central European Caucasians and spread over the world by migration. (C) 1997 Wiiey-Liss, Inc.
引用
收藏
页码:403 / 411
页数:9
相关论文
共 50 条
  • [1] Prevalence of factor V Leiden mutation in non-European populations
    Pepe, G
    Rickards, O
    Vanegas, OC
    Brunelli, T
    Gori, AM
    Giusti, B
    Attanasio, M
    Prisco, D
    Gensini, GF
    Abbate, R
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (02) : 329 - 331
  • [2] Prevalence of the factor V Leiden mutation in four distinct American ethnic populations
    Gregg, JP
    Yamane, AJ
    Grody, WW
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1997, 73 (03): : 334 - 336
  • [3] High prevalence of factor V mutation (Leiden) in the Eastern Mediterranean
    Irani-Hakime, N
    Tamim, H
    Elias, G
    Finan, RR
    Daccache, JL
    Almawi, WY
    CLINICAL CHEMISTRY, 2000, 46 (01) : 134 - 136
  • [4] Prevalence of the Factor V Leiden mutation in the Egyptian population.
    Hammoud, DF
    Eldibany, MM
    Nowak, JA
    BLOOD, 1996, 88 (10) : 3021 - 3021
  • [5] Hypercoagulability in various autoimmune diseases:: no association with factor V Leiden mutation
    Regéczy, N
    Balogh, I
    Lakos, G
    Zeher, M
    Bodolay, E
    Szücs, G
    Kiss, E
    Ajzner, E
    Szegedi, G
    HAEMATOLOGIA, 2000, 30 (01) : 35 - 39
  • [6] Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease
    Hagstrom, JN
    Walter, J
    Bluebond-Langner, R
    Amatniek, JC
    Manno, CS
    High, KA
    JOURNAL OF PEDIATRICS, 1998, 133 (06): : 777 - 781
  • [7] Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis
    Mahmoud, AEA
    Elias, E
    Beauchamp, N
    Wilde, JT
    GUT, 1997, 40 (06) : 798 - 800
  • [8] PREVALENCE OF THE FACTOR V LEIDEN MUTATION IN PATIENTS SUSCEPTIBLE TO VENOUS THROMBOEMBOLISM
    Mitrus, Joanna Malgorzata
    Wierszylo, Elzbieta
    HEALTH PROBLEMS OF CIVILIZATION, 2020, 14 (02) : 83 - 93
  • [9] Increased prevalence of factor V Leiden mutation in neonatal intracranial haemorrhage
    Melegh, B
    Stankovics, J
    Kis, A
    Nagy, A
    Storcz, J
    Losonczy, H
    Méhes, K
    EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (03) : 261 - 261
  • [10] Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals
    Ali A. Dashti
    Mehrez M. Jadaon
    Molecular Biology Reports, 2011, 38 : 3623 - 3628